论文部分内容阅读
目的:对替罗非班在急性心肌梗塞中的临床效果进行了探究。方法:文章在研究中,选择了本院2011年1月至2016年7月的80例急性心肌梗塞患者,均在发病后进行了急诊介入治疗,将80例患者随机分为观察组及对照组,每组患者40例,对照组患者口服阿司匹林、氯吡格雷,并在皮下注射低分子肝素。观察组患者在对照组治疗的基础上,手术时开始使用替罗非班,持续泵入到手术之后的36小时。通过对两组患者治疗变化的分析,确定不良反应的发生。结果:通过对比分析,两组患者在性别、年龄以及合并症等方面均无明显的差异(P<0.05),具有可比性。两组患者在疗效以及安全性比较分析中,评价项目无明显差异(P<0.05),具有可比性。结论:在急性心肌梗塞患者治疗的过程中,使用替罗非班可以减少患者术后心源性死亡、再次心肌梗塞等现象的发生,并改善患者的心脏功能,值得在临床治疗中得到推广。
Objective: To investigate the clinical effect of tirofiban in acute myocardial infarction. Methods: In this study, 80 patients with acute myocardial infarction from January 2011 to July 2016 were selected to undergo emergency intervention after the onset of disease. Eighty patients were randomly divided into observation group and control group , 40 patients in each group, the control group of patients taking aspirin, clopidogrel, and subcutaneous injection of low molecular weight heparin. Patients in the observation group, on the basis of treatment in the control group, started tirofiban at the time of surgery and continued to pump 36 hours after the operation. Through the treatment of two groups of patients with changes in the analysis to determine the occurrence of adverse reactions. Results: By comparative analysis, there was no significant difference (P <0.05) between the two groups in terms of gender, age and comorbidity, which is comparable. Two groups of patients in the efficacy and safety of comparative analysis, the evaluation of the project no significant difference (P <0.05), comparable. Conclusion: Tirofiban can reduce the occurrence of postoperative cardiac death, reoccurrence of myocardial infarction and improve cardiac function in patients with acute myocardial infarction. It is worth to be promoted in clinical treatment.